title: Topical adapalene in the treatment of plantar warts; randomized comparative open trial in comparison with cryo-therapy.
abstract: BACKGROUND
  Various therapeutic modalities, which are available for treating plantar wart, have not been successful every time.
  
  
  OBJECTIVE
  To evaluate topical adapalene under occlusion in the treatment of plantar warts and compare it with cryo-therapy.
  
  
  METHODS
  50 patients with 424 plantar warts were included in this single center, two arm, prospective, randomized, control, open study. Patients were allocated randomly into two groups consisting of 25 patients each. Group A patients having 299 plantar warts were treated using adapalene gel 0.1% under occlusion while Group B patients having 125 warts were treated using cryo-therapy. All the patients were evaluated weekly till the clearance of all the warts and the results compared.
  
  
  RESULTS
  All the warts of 25 patients of Group A that were treated using adapalene gel 0.1% cleared in 36.71 ± 19.24 (55.95-17.47) days except those in one patient. In Group B, warts in all except one treated by cryo-therapy cleared in 52.17 ± 30.06 (82.23-22.11) days. There were no side effects like scar formation, irritation, erythema, or infections with adapalene group while in the cryo group scar was seen in 2 patients, pain in 24, erythema in 10, and infection in 3 patients.
  
  
  CONCLUSIONS
  Adapalene gel 0.1% under occlusion is an effective, safe and easy to use treatment for plantar warts and may help clear lesions faster than cryo-therapy.
authors: Department of Dermatology, Indraprastha Apollo Hospital, Sarita Vihar, New Delhi, India.
authors: Ramji
authors: R
authors: Gupta
authors: Department of Rheumatology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Health, Bethesda, Maryland, USA.
authors: Sarthak
authors: S
authors: Gupta
keywords: Adapalene; cryo-therapy; occlusion; plantar wart
references: J Invest Dermatol. 1992 Feb;98(2):128-34
references: 1370673
references: Lancet. 1992 Jul 4;340(8810):48-9
references: 1351617
references: Br J Dermatol. 2001 Jan;144(1):4-11
references: 11167676
references: Am Fam Physician. 2005 Aug 15;72(4):647-52
references: 16127954
references: Indian J Dermatol. 2011 Sep-Oct;56(5):513-4
references: 22121266
references: J Am Podiatry Assoc. 1979 Dec;69(12):713-6
references: 521593
references: Drugs. 1997 Mar;53(3):511-9
references: 9074847
references: Pediatr Dermatol. 1987 Nov;4(3):254-8
references: 3321005
references: Cochrane Database Syst Rev. 2012 Sep 12;(9):CD001781
references: 22972052
references: J Drugs Dermatol. 2003 Apr;2(2):124-6
references: 12905977
references: Australas J Dermatol. 1999 May;40(2):93-5
references: 10333620
references: Eur J Dermatol. 2002 Jul-Aug;12 (4):347-9
references: 12095879
references: Int J Dermatol. 1980 Jul-Aug;19(6):342-3
references: 7005134
references: Pediatr Dermatol. 2002 May-Jun;19(3):263-6
references: 12047649
references: Int J Dermatol. 2006 Apr;45(4):480-2
references: 16650187
references: BMJ. 2002 Aug 31;325(7362):461
references: 12202325
references: Agents Actions. 1990 Jan;29(1-2):56-8
references: 2109510
references: J Am Acad Dermatol. 1996 Mar;34(3):482-5
references: 8609263
references: Skin Pharmacol. 1993;6 Suppl 1:61-9
references: 8142113